THERAPY DOSSIER · th-f768191e804a

Milnacipran

Drug · Serotonin transporter inhibitor; Norepinephrine transporter inhibitor (INHIBITOR, direct interaction)

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Serotonin transporter inhibitor; Norepinephrine transporter inhibitor (INHIBITOR, direct interaction)
Target: CHEMBL228 (serotonin transporter); CHEMBL222 (norepinephrine transporter)
Injury models: Other
Reported indication: Not recorded
First approval: 2009
Development stage: Not recorded
ChEMBL record: CHEMBL259209 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Impulsor; Milnacipran; Milnacipran hydrochloride
Note: Not recorded

Clinical trials 8

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01288807 ↗PHASE4completed

Effects of 12 Week Milnacipran 200 mg Treatment on Pain Perception and Processing in Fibromyalgia

Fibromyalgia

Enrolment: 8 · Results not recorded

NCT01780389 ↗PHASE4completed

Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty

Knee Pain After Total Knee Arthroplasty · Osteoarthritis Pain

Enrolment: 5 · Results not recorded

NCT03249311 ↗PHASE4unknown

Effectiveness of Levomilnacipran in Healthy Males

Healthy Volunteers

Enrolment: 36 · Results not recorded

NCT00436033 ↗PHASE3completed

European Phase III Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia Syndrome

Fibromyalgia Syndrome

Enrolment: 1429 · Results not recorded

NCT00098124 ↗PHASE3completed

Phase III Pivotal Study of Milnacipran for the Treatment of Fibromyalgia

Fibromyalgia

Enrolment: 1200 · Results not recorded

NCT01471379 ↗PHASE2terminated

Efficacy of Milnacipran in the Treatment of Irritable Bowel Syndrome

Irritable Bowel Syndrome

Enrolment: 2 · Results not recorded

NCT01331109 ↗PHASE2terminated

52-Week Extension Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia

Primary Fibromyalgia

Enrolment: 57 · Results not recorded

NCT03905486 ↗NAcompleted

Pregabalin Monotherapy Versus Combined Pregabalin and Milnacipran in Fibromyalgia

Fibromyalgia, Primary

Enrolment: 58 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21277295 ↗2011Reported benefit

Evaluation of milnacipran, in comparison with amitriptyline, on cold and mechanical allodynia in a rat model of neuropathic pain.

RatOtherIntraperitonealMinimum effective dose 2.5 mg/kg (cold), 10 mg/kg (mechanic…After established neuropathy

Model: Chronic constriction injury of the sciatic nerve

Milnacipran reduced both cold and mechanical allodynia and was as efficacious as amitriptyline in nerve constriction-induced neuropathic pain.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…